Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00478075 · ClinicalTrials.gov registry record · Phase 1

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
50
Enrollment target
3
Study locations

NCT00478075 is a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Mayo Clinic. The registered enrollment target is 50 participants, below the 768-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00478075, a Phase 1 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
50 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Bortezomib may also make cancer cells more sensitive to radiation therapy. Giving samarium Sm 153 lexidronam pentasodium together with bortezomib may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when given together with samarium Sm 153 lexidronam pentasodium and to see how well they work in treating patients with relapsed or refractory multiple myeloma.

Conditions Studied

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

  • DRUG bortezomib
  • OTHER immunologic technique
  • RADIATION samarium Sm 153 lexidronam pentasodium

Study Locations (3)

Arizona

  • Mayo Clinic Scottsdale - Scottsdale

Florida

  • Mayo Clinic - Jacksonville - Jacksonville

Minnesota

  • Mayo Clinic Cancer Center - Rochester

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2005-09
Est. Completion 2009-06
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00478075

The ClinicalTrials.gov registry entry for NCT00478075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 768-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (93% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which bortezomib is the first listed.

NCT00478075 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00478075 about?

NCT00478075 is a clinical study titled "Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma". RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Bortez...

What is the current status of trial NCT00478075?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2005-09. Estimated completion is 2009-06.

What conditions does trial NCT00478075 study?

This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.

What interventions are being tested in trial NCT00478075?

The interventions under investigation include: bortezomib (DRUG), immunologic technique (OTHER), samarium Sm 153 lexidronam pentasodium (RADIATION).

Who is sponsoring clinical trial NCT00478075?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00478075 being conducted?

This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma and Plasma Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma and Plasma Cell Neoplasm

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.